It disrupts the interaction between LAG-3 and MHC II molecules, enhancing the production of key cytokines and expression of activation markers in T cells.352 Favezelimab’s safety and efficacy profiles are currently being evaluated in a phase I/II clinical trial in combination with pembrolizumab.353 Initial results suggest a manageable safety profile, paving the way for further studies on LAG-3 targeted therapies in CRC. The gene discussed is LAG3; the disease is colorectal carcinoma.